Literature DB >> 28102980

Microbiology Devices; Reclassification of Influenza Virus Antigen Detection Test Systems Intended for Use Directly With Clinical Specimens. Final order.

.   

Abstract

The Food and Drug Administration (FDA) is reclassifying antigen based rapid influenza virus antigen detection test systems intended to detect influenza virus directly from clinical specimens that are currently regulated as influenza virus serological reagents from class I into class II with special controls and into a new device classification regulation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28102980

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  12 in total

Review 1.  Pharmacy-Based Infectious Disease Management Programs Incorporating CLIA-Waived Point-of-Care Tests.

Authors:  S R Herbin; D G Klepser; M E Klepser
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

Review 2.  Rapid Antigen Tests for Influenza: Rationale and Significance of the FDA Reclassification.

Authors:  Daniel A Green; Kirsten StGeorge
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

3.  Direct Comparison of Alere i and cobas Liat Influenza A and B Tests for Rapid Detection of Influenza Virus Infection.

Authors:  Frederick S Nolte; Lori Gauld; Susan B Barrett
Journal:  J Clin Microbiol       Date:  2016-08-31       Impact factor: 5.948

4.  Can newly developed, rapid immunochromatographic antigen detection tests be reliably used for the laboratory diagnosis of influenza virus infections?

Authors:  James J Dunn; Christine C Ginocchio
Journal:  J Clin Microbiol       Date:  2014-10-01       Impact factor: 5.948

5.  Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections.

Authors:  Carmen L Charlton; Esther Babady; Christine C Ginocchio; Todd F Hatchette; Robert C Jerris; Yan Li; Mike Loeffelholz; Yvette S McCarter; Melissa B Miller; Susan Novak-Weekley; Audrey N Schuetz; Yi-Wei Tang; Ray Widen; Steven J Drews
Journal:  Clin Microbiol Rev       Date:  2018-12-12       Impact factor: 26.132

6.  Influenza Antiviral Prescribing Practices and the Influence of Rapid Testing Among Primary Care Providers in the US, 2009-2016.

Authors:  Ashley L Fowlkes; Andrea Steffens; Carrie Reed; Jonathan L Temte; Angela P Campbell
Journal:  Open Forum Infect Dis       Date:  2019-04-26       Impact factor: 3.835

7.  Diagnostic Accuracy of the Quidel Sofia Rapid Influenza Fluorescent Immunoassay in Patients with Influenza-like Illness: A Systematic Review and Meta-analysis.

Authors:  Jonghoo Lee; Jae-Uk Song; Yee Hyung Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2021-05-13

8.  Rapid Influenza Testing in an Austere Setting, Mongolia.

Authors:  Chuluunbaatar Maisetseg; Daramragchaa Ulziimaa; Alexandra Sack; Gonchigoo Battsetseg; Baigalmaa Bekh-Ochir; Myagmarsukh Yondon; Gregory C Gray
Journal:  Open Forum Infect Dis       Date:  2017-10-26       Impact factor: 3.835

Review 9.  Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives.

Authors:  Philipp P Nelson; Barbara A Rath; Paraskevi C Fragkou; Emmanouil Antalis; Sotirios Tsiodras; Chrysanthi Skevaki
Journal:  Front Cell Infect Microbiol       Date:  2020-04-29       Impact factor: 5.293

10.  Readiness for Responding to a Severe Pandemic 100 Years After 1918.

Authors:  Barbara Jester; Timothy Uyeki; Daniel Jernigan
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.